- Home
- MYNZ vs BDRX Comparison
MYNZ vs BDRX Comparison
Compare MYNZ & BDRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | BDRX |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | Germany | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 4.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYNZ | BDRX |
|---|---|---|
| Price | $1.22 | $3.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 188.9K | ★ 2.6M |
| Earning Date | 12-29-2025 | 09-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $659,935.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $3.55 |
| 52 Week High | $8.20 | $92.00 |
Technical Indicators
Market Signals| Indicator | MYNZ | BDRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 42.91 |
| Support Level | $1.00 | $4.55 |
| Resistance Level | $1.15 | $7.22 |
| Average True Range (ATR) | 0.08 | 1.51 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 76.27 | 1.67 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.